The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107

Leukemia. 2005 Sep;19(9):1670-1. doi: 10.1038/sj.leu.2403887.
No abstract available

Publication types

  • Letter

MeSH terms

  • Amino Acid Substitution
  • Animals
  • Apoptosis / drug effects
  • Benzamides
  • Cell Line
  • Cell Proliferation / drug effects
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Imatinib Mesylate
  • Mastocytosis, Systemic / genetics*
  • Mice
  • Mutation
  • Piperazines / pharmacology
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-kit / drug effects*
  • Proto-Oncogene Proteins c-kit / genetics*
  • Pyrimidines / pharmacology*

Substances

  • Benzamides
  • Enzyme Inhibitors
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins c-kit
  • nilotinib